Target Profiling of Small Molecules by Chemical Proteomics

Overview

Journal Nat Chem Biol

Specialties Biochemistry
Biology
Chemistry

Date 2009 Aug 20

PMID 19690537

Citations 198

Authors

Uwe Rix

Giulio Superti-Furga

Affiliations

Soon will be listed here.

Abstract

The medical and pharmaceutical communities are facing a dire need for new druggable targets, while, paradoxically, the targets of some drugs that are in clinical use or development remain elusive. Many compounds have been found to be more promiscuous than originally anticipated, which can potentially lead to side effects, but which may also open up additional medical uses. As we move toward systems biology and personalized medicine, comprehensively determining small molecule-target interaction profiles and mapping these on signaling and metabolic pathways will become increasingly necessary. Chemical proteomics is a powerful mass spectrometry-based affinity chromatography approach for identifying proteome-wide small molecule-protein interactions. Here we will provide a critical overview of the basic concepts and recent advances in chemical proteomics and review recent applications, with a particular emphasis on kinase inhibitors and natural products.

Citing Articles

Decoding nature: multi-target anti-inflammatory mechanisms of natural products in the TLR4/NF-κB pathway.

Zhao Y, Wu J, Liu X, Chen X, Wang J Front Pharmacol. 2025; 15:1467193.

PMID: 39877388 PMC: 11772364. DOI: 10.3389/fphar.2024.1467193.

Proteins and DNA Sequences Interacting with Tanshinones and Tanshinone Derivatives.

Szymczyk P, Majewska M, Nowak J Int J Mol Sci. 2025; 26(2).

PMID: 39859562 PMC: 11765770. DOI: 10.3390/ijms26020848.

Phenomics-Based Discovery of Novel Orthosteric Choline Kinase Inhibitors.

Bauer L, Ward J, Diaz-Saez L, Sundstrom Y, Tolvanen T, Alarcon Barrera J Angew Chem Int Ed Engl. 2024; 64(7):e202420149.

PMID: 39740997 PMC: 11811597. DOI: 10.1002/anie.202420149.

Improving compound-protein interaction prediction by focusing on intra-modality and inter-modality dynamics with a multimodal tensor fusion strategy.

Wang M, Wang J, Ji J, Ma C, Wang H, He J Comput Struct Biotechnol J. 2024; 23:3714-3729.

PMID: 39525082 PMC: 11544084. DOI: 10.1016/j.csbj.2024.10.004.

AI-empowered perturbation proteomics for complex biological systems.

Qian L, Sun R, Aebersold R, Buhlmann P, Sander C, Guo T Cell Genom. 2024; 4(11):100691.

PMID: 39488205 PMC: 11605689. DOI: 10.1016/j.xgen.2024.100691.

References

Wan Y, Hur W, Cho C, Liu Y, Adrian F, Lozach O . Synthesis and target identification of hymenialdisine analogs. Chem Biol. 2004; 11(2):247-59. DOI: 10.1016/j.chembiol.2004.01.015. View

Chen J, Lane W, Schreiber S . The identification of myriocin-binding proteins. Chem Biol. 1999; 6(4):221-35. DOI: 10.1016/S1074-5521(99)80038-6. View

Schena M, Shalon D, Davis R, Brown P . Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science. 1995; 270(5235):467-70. DOI: 10.1126/science.270.5235.467. View

Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B . A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26(1):127-32. DOI: 10.1038/nbt1358. View

Brehmer D, Godl K, Zech B, Wissing J, Daub H . Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics. 2004; 3(5):490-500. DOI: 10.1074/mcp.M300139-MCP200. View

Mizuarai S, Irie H, Schmatz D, Kotani H . Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med. 2008; 8(8):774-83. DOI: 10.2174/156652408786733676. View

Duncan J, Gyenis L, Lenehan J, Bretner M, Graves L, Haystead T . An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics. 2008; 7(6):1077-88. DOI: 10.1074/mcp.M700559-MCP200. View

Feher M, Schmidt J . Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci. 2003; 43(1):218-27. DOI: 10.1021/ci0200467. View

Verhelst S, Fonovic M, Bogyo M . A mild chemically cleavable linker system for functional proteomic applications. Angew Chem Int Ed Engl. 2007; 46(8):1284-6. DOI: 10.1002/anie.200603811. View

10.

Adam G, Vanderwal C, Sorensen E, Cravatt B . (-)-FR182877 is a potent and selective inhibitor of carboxylesterase-1. Angew Chem Int Ed Engl. 2003; 42(44):5480-4. DOI: 10.1002/anie.200352576. View

11.

Piggott A, Karuso P . Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Comb Chem High Throughput Screen. 2004; 7(7):607-30. DOI: 10.2174/1386207043328409. View

12.

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

13.

Kruse U, Bantscheff M, Drewes G, Hopf C . Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol Cell Proteomics. 2008; 7(10):1887-901. DOI: 10.1074/mcp.R800006-MCP200. View

14.

Remsing Rix L, Rix U, Colinge J, Hantschel O, Bennett K, Stranzl T . Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia. 2008; 23(3):477-85. DOI: 10.1038/leu.2008.334. View

15.

Quintas-Cardama A, Kantarjian H, Cortes J . Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007; 6(10):834-48. DOI: 10.1038/nrd2324. View

16.

Ong S, Schenone M, Margolin A, Li X, Do K, Doud M . Identifying the proteins to which small-molecule probes and drugs bind in cells. Proc Natl Acad Sci U S A. 2009; 106(12):4617-22. PMC: 2649954. DOI: 10.1073/pnas.0900191106. View

17.

Ge X, Sem D . Affinity-based chemical proteomic probe for dehydrogenases: fluorescence and visible binding assays in gels. Anal Biochem. 2007; 370(2):171-9. DOI: 10.1016/j.ab.2007.08.010. View

18.

Hillenmeyer M, Fung E, Wildenhain J, Pierce S, Hoon S, Lee W . The chemical genomic portrait of yeast: uncovering a phenotype for all genes. Science. 2008; 320(5874):362-5. PMC: 2794835. DOI: 10.1126/science.1150021. View

19.

Cohen A, Geva-Zatorsky N, Eden E, Frenkel-Morgenstern M, Issaeva I, Sigal A . Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008; 322(5907):1511-6. DOI: 10.1126/science.1160165. View

20.

Van der Veken P, Dirksen E, Ruijter E, Elgersma R, Heck A, Rijkers D . Development of a novel chemical probe for the selective enrichment of phosphorylated serine- and threonine-containing peptides. Chembiochem. 2005; 6(12):2271-80. DOI: 10.1002/cbic.200500209. View